Ovarian Cancer

Clinical trial data show ovarian cancer survival gaps narrow with diverse enrollment, but disparities persist after progression, spotlighting access, toxicity, and care barriers.

Phase 2 data show elenagen plus gemcitabine extends survival in platinum-resistant ovarian cancer with high CA-125, without added toxicity.

FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in clinical trials.

A recent study reveals significant racial disparities in ovarian cancer trial outcomes, highlighting the urgent need for improved diversity in clinical research.

Gemogenovatucel-T shows remarkable survival benefits in high-risk ovarian cancer patients, highlighting its potential as a new standard of care.

BioInvent's BI-1808 combined with pembrolizumab shows promising antitumor activity in recurrent ovarian cancer, offering hope for better treatment options.

The ROSELLA trial reveals relacorilant plus nab-paclitaxel significantly improves survival in platinum-resistant ovarian cancer without increasing safety risks.

New cancer vaccine MVP-S shows promising results in recurrent ovarian cancer, enhancing immune response and improving treatment outcomes with pembrolizumab.

Sofetabart mipitecan receives FDA breakthrough therapy designation, showing promising efficacy in treating platinum-resistant ovarian cancer.

The SCORES trial reveals suvemcitug significantly enhances survival and disease control in patients with platinum-resistant recurrent ovarian cancer.

A systematic review reveals PARP inhibitors improve progression-free survival in advanced ovarian cancer but lack overall survival benefits, highlighting treatment variability.

ETX-19477 receives FDA fast track designation, promising accelerated development for treating BRCA-mutated, platinum-resistant ovarian cancer patients.

A novel antibody combination shows promising results in treating recurrent ovarian cancer, offering hope for better immunotherapy options.

A phase 2 trial shows ribociclib and letrozole effectively treat recurrent low-grade serous carcinoma, achieving significant response rates and durable control.

JSKN003, a novel HER2-targeting ADC, shows promising efficacy in treating platinum-resistant ovarian cancer, earning FDA breakthrough therapy designation.

A recent trial evaluates the impact of dostarlimab on ovarian cancer treatment, revealing modest benefits and no significant safety concerns with niraparib.

The FDA fast-tracks JSKN003, a promising treatment for platinum-resistant ovarian cancer, enhancing development and approval processes for this critical therapy.

Recent findings from the MIRASOL trial reveal significant advancements in treatment options for platinum-resistant ovarian cancer, emphasizing effective therapy sequencing.

New findings reveal that adding sapanisertib to weekly paclitaxel significantly improves progression-free survival in advanced ovarian cancer patients.

Raludotatug deruxtecan (R-DXd) demonstrates significant antitumor activity and manageable safety in platinum-resistant ovarian cancer, paving the way for further studies.

TUB-040 shows over 50% response rates in platinum-resistant ovarian cancer, highlighting its potential as a promising treatment option.

New findings reveal pembrolizumab combined with paclitaxel enhances survival rates in patients with platinum-resistant recurrent ovarian cancer.

During a live event, Martin A. Martino, MD, analyzed overall survival outcomes from the PAOLA-1, SOLO-1, and PRIMA trials.

New clinical data reveals stenoparib significantly extends survival in advanced platinum-resistant ovarian cancer, offering hope for patients with limited options.

IMNN-001 shows promising results in enhancing the tumor microenvironment and improving survival rates in advanced ovarian cancer treatment.